Tregs and Rethinking cancer immunotherapy… Ipilimumab surpresses the Treg function to shift the immune system into activation

Tregs and rethinking cancer immunotherapy
Tyler J. Curiel

San Antonio Cancer Institute, University of Texas Health Sciences Center, and Cancer Therapy & Research Center, San Antonio, Texas, USA.
Address correspondence to: Tyler J. Curiel, San Antonio Cancer Institute, University of Texas Health Sciences Center, 7703 Floyd Curl Drive, San Antonio, Texas 78229-3900, USA. Phone: (210) 562-5286; Fax: (210) 562-5292; E-mail: [email protected].

Tregs and rethinking cancer immunotherapy
Tyler J. Curiel

San Antonio Cancer Institute, University of Texas Health Sciences Center, and Cancer Therapy & Research Center, San Antonio, Texas, USA.
Address correspondence to: Tyler J. Curiel, San Antonio Cancer Institute, University of Texas Health Sciences Center, 7703 Floyd Curl Drive, San Antonio, Texas 78229-3900, USA. Phone: (210) 562-5286; Fax: (210) 562-5292; E-mail: [email protected].

Tumors express antigens that should induce immune-mediated rejection, but spontaneous rejection of established tumors is rare. Recent work demonstrates that one reason for the lack of tumor rejection is that tumors actively defeat host immunity. This concept forces us to rethink current approaches to harnessing potent, specific host immunity to battle cancer, most of which are based on the paradigm that inducing more antitumor immune cells alone is therapeutic. However, as I discuss in this Personal Perspective, a newer paradigm predicts that reducing tumor-driven immune suppression will be clinically beneficial. CD4+CD25+ Tregs are one mechanism of tumor-driven immune evasion that provide prototypical targets for testing novel anticancer treatment strategies within the newer paradigm.

Abstract
Introduction

Tumors express antigens that should induce immune-mediated rejection, but spontaneous rejection of established tumors is rare. Recent work demonstrates that one reason for the lack of tumor rejection is that tumors actively defeat host immunity. This concept forces us to rethink current approaches to harnessing potent, specific host immunity to battle cancer, most of which are based on the paradigm that inducing more antitumor immune cells alone is therapeutic. However, as I discuss in this Personal Perspective, a newer paradigm predicts that reducing tumor-driven immune suppression will be clinically beneficial. CD4+CD25+ Tregs are one mechanism of tumor-driven immune evasion that provide prototypical targets for testing novel anticancer treatment strategies within the newer paradigm.

Source:  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1857250/

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1857250 – Tregs and rethinking cancer immunotherapy

This paper is one of the better ones for understanding the whole Treg Thing. Ipilimumasb and Interluekin-2  in combination will change the paradigm in novel anticancer treatment strategies as we see it today and may hold the key to durable remissions of melanoma.

Take care

Jimmy B